Peking University Medicine: Announcement on No Profit Distribution in 2025
Securities code: 000788 Securities abbreviation: Peking University Medicine Announcement number: 2026-016
Peking University Pharmaceutical Co., Ltd.
Announcement on No Profit Distribution in 2025
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Review procedure
- Review status of the board of directors
Peking University Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 19th meeting of the 11th Board of Directors on April 24, 2026, and reviewed and approved the "2025 Profit Distribution Plan" with 9 votes in favor, 0 votes against, 0 votes to avoid, and 0 abstentions.
- Deliberations at special meetings of independent directors
The company's independent directors held the 10th special meeting of independent directors of the 11th board of directors on April 23, 2026, and reviewed and approved the "2025 Profit Distribution Plan" with 3 votes in favor, 0 votes against, and 0 abstentions.
After deliberation, the independent directors believe that the company's 2025 profit distribution plan comprehensively considers the company's development strategy, profit prospects, future capital use needs, asset conditions, market environment and other factors, matches the company's performance growth, is in line with the company's actual situation, and takes into account the company's sustainable and healthy development. This plan complies with the provisions of the "Company Law", "Listed Company Supervision Guidelines No. 3 - Cash Dividends of Listed Companies" and the "Articles of Association". It does not harm the interests of the company's shareholders, especially small and medium-sized shareholders. It is agreed that the "2025 Profit Distribution Plan" will be submitted to the company's board of directors for review.
- Review status of the Audit Committee of the Board of Directors
Members of the Audit Committee of the company's Board of Directors held the 11th meeting of the Audit Committee of the 11th Board of Directors on April 23, 2026, and reviewed and approved the "2025 Profit Distribution Plan" with 3 votes in favor, 0 votes against, and 0 abstentions.
After deliberation, the Audit Committee of the Board of Directors believes that the company's 2025 profit distribution plan comprehensively considers the company's development strategy, profit prospects, future capital use needs, asset conditions, market environment and other factors, matches the company's performance growth, is in line with the company's actual situation, and takes into account the company's sustainable and healthy development. This plan complies with the provisions of the "Company Law", "Listed Company Supervision Guidelines No. 3 - Cash Dividends of Listed Companies" and the "Articles of Association". It does not harm the interests of the company's shareholders, especially small and medium-sized shareholders. It is agreed to submit the "2025 Profit Distribution Plan" to the company's board of directors for review.
2. Basic situation of profit distribution plan for 2025
This profit distribution plan is the profit distribution plan for 2025.
After auditing by Tianjian Accounting Firm (Special General Partnership) (hereinafter referred to as "Tianjian Club"), the company's net profit attributable to shareholders of the listed company in 2025 was 82,882,957.79 yuan, of which the parent company's net profit was 244,052,922.23 yuan (including 200,000,000.00 yuan in dividends from subsidiaries) Yuan), in accordance with the provisions of the Company Law and the Articles of Association, a statutory surplus reserve fund of RMB 24,405,292.22 will be withdrawn in 2025. Including the undistributed profits of RMB 117,699,480.72 in previous years, and deducting the actual distributed cash dividends for 2024 and 2025 half-year of RMB 35,759,245.50 in 2025, the profit available for distribution to shareholders at the end of 2025 is RMB 301,587,865.23.
The company’s profit distribution plan for 2025 is: no profit distribution is planned. No cash dividends will be distributed, no bonus shares will be issued, and capital reserve funds will not be converted into share capital.
The company's cumulative cash dividend amount in 2025 is 118,005,510.15 yuan, accounting for 142.38% of the net profit attributable to shareholders of the listed company in 2025.
3. Details of the profit distribution plan for 2025
(1) Profit distribution plan for 2025
The 2025 profit distribution plan does not touch other risk warning situations stipulated in the Stock Listing Rules of the Shenzhen Stock Exchange.
Item 2025 2024 Total cash dividends in 2023 (yuan) 118,005,510.15 47,678,994.00 15,495,673.04 Total repurchase and cancellation (yuan) - - -
Net profit attributable to shareholders of listed companies (yuan) 82,882,957.79 137,992,604.73 44,356,578.25 Consolidated statements Accumulated undistributed profits at the end of the year (yuan) 679,775,660.59
Accumulated undistributed profits at the end of the year in the parent company’s statement (yuan) 301,587,865.23
Whether the listing has been completed for three complete fiscal years? Yes
Total cumulative cash dividends in the last three fiscal years (yuan) 181,180,177.19
Cumulative total repurchase and write-off in the past three fiscal years (yuan) 0
Average net profit for the last three fiscal years (yuan) 88,410,713.59
Cumulative total cash dividends and repurchase cancellations in the past three fiscal years (yuan) 181,180,177.19
Whether it violates the provisions of Article 9.8.1 (9) of the Stock Listing Rules and may be subject to
No
Implement other risk warning situations
(2) Reasonable explanation of the profit distribution plan for 2025
Since the amount of dividends implemented by the company for the first half of 2025 and the first three quarters of 2025 has far exceeded 30% of the average profit of the past three fiscal years, coupled with the intensification of competition in the generic drug market, the company will focus more on the development of its main pharmaceutical business, increase its efforts in anti-infectious, analgesic, psychiatric, chronic disease and other drug fields, and accelerate product structure adjustment. The company has the possibility of large-scale capital expenditures in 2026. Therefore, after comprehensive consideration, the board of directors decided that the profit distribution plan for 2025 is not to distribute profits, distribute cash dividends, issue bonus shares, and not convert capital reserve funds into share capital.
The profit distribution plan is in compliance with the relevant provisions on profit distribution in the China Securities Regulatory Commission's "Notice on Further Implementing Matters Related to Cash Dividends by Listed Companies", "Regulatory Guidelines for Listed Companies No. 3 - Cash Dividends by Listed Companies" and the "Articles of Association" and the relevant provisions on profit distribution. It fully takes into account comprehensive factors such as the company's 2025 profitability, future development capital needs, and shareholder investment returns. It does not harm the interests of small and medium-sized shareholders and is in line with the company's long-term development needs. Retained undistributed profits will be carried forward to subsequent years and used to supplement daily working capital, carry out strategic investments, etc., to further enhance the company's value creation capabilities and reward shareholders with better performance. The company does not have a raised capital account, so there is no situation where it has used raised funds to replenish working capital in the past twelve months and does not plan to use raised funds to replenish working capital in the next twelve months.
4. Related risk warnings
The "2025 Profit Distribution Plan" still needs to be submitted to the company's shareholders' meeting for review. Investors are kindly requested to invest rationally and pay attention to investment risks.
5. Documents for reference
"Resolution of the 19th Meeting of the 11th Board of Directors"
"Audit Opinions on Related Matters at the Tenth Special Meeting of Independent Directors of the Eleventh Board of Directors"
"Resolution of the Eleventh Meeting of the Audit Committee of the Eleventh Board of Directors"
Announcement is hereby made.
Board of Directors of Peking University Pharmaceutical Co., Ltd.
April 28, 2026